| | |
Per share
and accompanying common warrant |
| |
Per pre-funded warrant
and accompanying common warrant |
| |
Total
|
| |||||||||
合并公开发行价格
|
| | | $ | 0.43 | | | | | $ | 0.429 | | | | | $ | 10,000,000 | | |
承保折扣和佣金(1)
|
| | | $ | 0.028 | | | | | $ | 0.028 | | | | | $ | 652,086 | | |
未扣除费用的收益给我们
|
| | | $ | 0.402 | | | | | $ | 0.401 | | | | | $ | 9,347,913 | | |
| | |
Page
|
| |||
关于本招股说明书副刊
|
| | | | S-1 | | |
前瞻性陈述
|
| | | | S-2 | | |
SUMMARY
|
| | | | S-3 | | |
THE OFFERING
|
| | | | S-10 | | |
RISK FACTORS
|
| | | | S-12 | | |
USE OF PROCEEDS
|
| | | | S-14 | | |
DILUTION
|
| | | | S-15 | | |
我们提供的证券说明
|
| | | | S-16 | | |
UNDERWRITING
|
| | | | S-20 | | |
LEGAL MATTERS
|
| | | | S-24 | | |
EXPERTS
|
| | | | S-24 | | |
您可以在哪里找到更多信息
|
| | | | S-24 | | |
引用合并
|
| | | | S-24 | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
您可以在哪里找到更多信息
|
| | | | 2 | | |
引用合并
|
| | | | 3 | | |
关于前瞻性陈述的特别说明
|
| | | | 4 | | |
THE COMPANY
|
| | | | 5 | | |
RISK FACTORS
|
| | | | 9 | | |
USE OF PROCEEDS
|
| | | | 10 | | |
债务证券说明
|
| | | | 11 | | |
股本说明
|
| | | | 18 | | |
其他证券说明
|
| | | | 20 | | |
PLAN OF DISTRIBUTION
|
| | | | 22 | | |
LEGAL MATTERS
|
| | | | 25 | | |
EXPERTS
|
| | | | 25 | | |
Branded Product
|
| |
Approved Indication
|
| |
FDA Approval Date
|
| |
Commercial Launch Date
|
|
Adzenys XR-ODT(苯丙胺) | | | 6岁及以上患者的ADHD治疗 | | | January 2016 | | | May 2016 | |
复方XR-ODT(哌酸甲酯) | | | 6至17岁ADHD患者的治疗 | | | June 2017 | | | September 2017 | |
|
普通股(或代替普通股的预融资权证)和配套认股权证的每股公开发行价
|
| |
|
| | | $ | 0.43 | | | |||
|
截至2022年3月31日的每股有形账面净值
|
| | | $ | (0.66) | | | | | | | | |
|
可归因于此次发行的每股收益增加
|
| | | $ | 0.43 | | | | | | | | |
|
本次发售生效后的调整后每股有形账面净值
|
| | | | | | | | | $ | (0.23) | | |
|
对新投资者的每股稀释(1)(2)
|
| | | | | | | | | $ | (0.66) | | |
Name
|
| |
Number of
shares |
| |
Number of
pre-funded warrants |
| |
Number of
Warrants |
| |||||||||
Cantor Fitzgerald & Co.
|
| | | | 13,978,780 | | | | | | 1,137,500 | | | | | | 15,116,280 | | |
Cannaccord Genuity LLC
|
| | | | 7,527,034 | | | | | | 612,500 | | | | | | 8,139,534 | | |
| | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | ||
Total
|
| | | | 21,505,814 | | | | | | 1,750,000 | | | | | | 23,255,814 | | |
| | | | | | | | | | | | |||||||||||
| | |
Per share
and accompanying common warrant |
| |
Per pre-funded warrant
and accompanying common warrant |
| |
Total
|
| | | | |||||||||
合并公开发行价格
|
| | | $ | 0.43 | | | | | $ | 0.429 | | | | | $ | 10,000,000 | | | | ||
承保折扣和佣金
|
| | | $ | 0.028 | | | | | $ | 0.028 | | | | | $ | 652,086 | | | | ||
未扣除费用的收益给我们
|
| | | $ | 0.402 | | | | | $ | 0.401 | | | | | $ | 9,347,913 | | | |
| | |
Page
|
| |||
ABOUT THIS PROSPECTUS
|
| | | | 1 | | |
您可以在哪里找到更多信息
|
| | | | 2 | | |
引用合并
|
| | | | 3 | | |
关于前瞻性陈述的特别说明
|
| | | | 4 | | |
THE COMPANY
|
| | | | 5 | | |
RISK FACTORS
|
| | | | 9 | | |
USE OF PROCEEDS
|
| | | | 10 | | |
债务证券说明
|
| | | | 11 | | |
股本说明
|
| | | | 18 | | |
其他证券说明
|
| | | | 20 | | |
PLAN OF DISTRIBUTION
|
| | | | 22 | | |
LEGAL MATTERS
|
| | | | 25 | | |
EXPERTS
|
| | | | 25 | | |
Branded Product
|
| |
Approved Indication
|
| |
FDA Approval Date
|
| |
Commercial Launch Date
|
|
Adzenys XR-ODT(苯丙胺) | | | 6岁及以上患者的ADHD治疗 | | | January 2016 | | | May 2016 | |
复方XR-ODT(哌酸甲酯) | | | 6至17岁ADHD患者的治疗 | | | June 2017 | | | September 2017 | |
Adzenys ER(苯丙胺)口服混悬剂 | | | 6岁及以上患者的ADHD治疗 | | | September 2017 | | | February 2018 | |